Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
ATXS

ATXS - Astria Therapeutics, Inc. Stock Price, Fair Value and News

8.99USD+0.16 (+1.81%)Delayed

Market Summary

ATXS
USD8.99+0.16
Delayed
1.81%

ATXS Stock Price

View Fullscreen

ATXS RSI Chart

ATXS Valuation

Market Cap

493.7M

Price/Earnings (Trailing)

-6.05

Price/Free Cashflow

-6.64

ATXS Price/Earnings (Trailing)

ATXS Profitability

Return on Equity

-22.2%

Return on Assets

-21.55%

Free Cashflow Yield

-15.05%

ATXS Fundamentals

ATXS Earnings

Earnings (TTM)

-81.6M

Earnings Growth (Yr)

-78.12%

Earnings Growth (Qtr)

36.56%

Breaking Down ATXS Revenue

Last 7 days

-1.0%

Last 30 days

-5.8%

Last 90 days

-42.8%

Trailing 12 Months

-8.4%

How does ATXS drawdown profile look like?

ATXS Financial Health

Current Ratio

33.83

ATXS Investor Care

Shares Dilution (1Y)

95.94%

Diluted EPS (TTM)

-2.4

Tracking the Latest Insider Buys and Sells of Astria Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 01, 2024
morabito christopher
sold
-135,939
13.5939
-10,000
chief medical officer
Apr 01, 2024
morabito christopher
acquired
38,700
3.87
10,000
chief medical officer
Feb 01, 2024
perceptive advisors llc
bought
29,999,500
12.09
2,481,350
-
Jan 29, 2024
morabito christopher
sold
-102,552
11.147
-9,200
chief medical officer
Jan 29, 2024
morabito christopher
acquired
35,604
3.87
9,200
chief medical officer
Jan 26, 2024
morabito christopher
sold
-8,812
11.015
-800
chief medical officer
Jan 26, 2024
morabito christopher
acquired
3,096
3.87
800
chief medical officer
Dec 21, 2023
perceptive advisors llc
bought
4,588,000
6.2
740,000
-
Oct 16, 2023
perceptive advisors llc
bought
7,000,000
6.514
1,074,610
-
Dec 19, 2022
perceptive advisors llc
bought
10,000,000
11.01
908,265
-

1–10 of 14

Which funds bought or sold ATXS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
Virtu Financial LLC
new
-
427,000
427,000
0.03%
May 17, 2024
Artal Group S.A.
new
-
12,445,300
12,445,300
0.32%
May 17, 2024
Ikarian Capital, LLC
reduced
-62.46
-898,347
1,980,170
0.22%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-7.92
28,754
70,572
-%
May 16, 2024
Tidal Investments LLC
new
-
1,663,660
1,663,660
0.03%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-15.59
168,366
476,158
-%
May 15, 2024
VR Adviser, LLC
added
11.87
26,017,500
50,791,700
2.42%
May 15, 2024
DEUTSCHE BANK AG\
added
45.71
213,327
340,961
-%
May 15, 2024
Driehaus Capital Management LLC
added
314
21,575,300
24,842,100
0.25%
May 15, 2024
STATE STREET CORP
added
319
27,173,400
31,241,900
-%

1–10 of 36

Are Funds Buying or Selling ATXS?

Are funds buying ATXS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ATXS
No. of Funds

Unveiling Astria Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 11, 2024
fmr llc
-
0
SC 13G/A
Mar 07, 2024
blackrock inc.
4.5%
2,455,653
SC 13G/A
Feb 14, 2024
deep track capital, lp
0%
0
SC 13G/A
Feb 14, 2024
fairmount funds management llc
9.9%
3,633,965
SC 13G/A
Feb 14, 2024
cormorant asset management, lp
0.00%
0
SC 13G/A
Feb 13, 2024
vivo opportunity, llc
4.5%
2,482,727
SC 13G/A
Feb 13, 2024
vanguard group inc
5.66%
2,055,707
SC 13G
Feb 12, 2024
ra capital management, l.p.
8.1%
4,413,150
SC 13G
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 05, 2024
perceptive advisors llc
11.9%
6,485,420
SC 13D/A

Recent SEC filings of Astria Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
8-K
Current Report
May 09, 2024
10-Q
Quarterly Report
Apr 22, 2024
ARS
ARS

Peers (Alternatives to Astria Therapeutics, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
0.28% 3.53%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.5B
2.0B
2.99% -23.67%
-58.61
9.71
75.20% 68.82%
16.0B
2.5B
8.50% -12.61%
77.77
6.46
13.74% 186.89%
13.8B
3.8B
7.60% -2.83%
18.51
3.66
8.58% 129.81%
MID-CAP
5.2B
107.9M
-8.24% 83.94%
-9.45
48.09
54.84% -28.31%
4.9B
524.1M
-2.95% -55.09%
-11.65
9.28
394.93% 39.61%
3.6B
251.0M
-0.68% -10.56%
-12.18
14.38
73.58% -86.73%
2.9B
240.7M
-4.80% -33.39%
-6.19
12.77
-1.03% -213.92%
2.5B
813.8M
0.54% -38.22%
-1.4K
3.02
56.43% 98.83%
1.9B
996.6M
5.92% 71.39%
-4.85
1.94
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.22% 22.70%
27.15
4.3
60.38% -34.49%
468.2M
881.7K
-2.64% 488.84%
-13.87
481.06
-77.61% 33.36%
221.8M
4.2M
-28.67% 45.58%
-1.78
53.32
-66.30% 48.24%
19.9M
2.1M
16.67% 230.00%
-0.86
7.61
-13.45% 69.54%

Astria Therapeutics, Inc. News

Latest updates
Defense World27 hours ago

Astria Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets48.7%37925519420721823112010511512813514114947.0057.0057.0059.0042.0044.0049.0054.00
  Current Assets49.2%37525119120421522811810411412713514014846.0056.0056.0057.0039.0043.0047.0053.00
    Cash Equivalents-2.0%17217612013420221.0046.0030.0047.0087.0013214014725.0053.0052.0013.0010.0018.0010.0012.00
  Net PPE---------------------0.00
Liabilities-4.1%11.0012.009.007.007.009.007.006.005.005.005.004.009.007.008.006.005.006.006.005.005.00
  Current Liabilities-4.1%11.0012.009.007.007.009.006.005.005.005.005.004.004.006.007.006.005.005.006.005.004.00
Shareholder's Equity51.3%36824318420021122111399.0011012213013733041.0049.000.0054.0036.0038.00254253
  Retained Earnings-3.4%-600-580-549-531-518-507-494-482-471-455-446-438-431-260-251-241-231-223-216-210-203
  Additional Paid-In Capital19.8%873728638636635633511486484482480475330302301292285259255254253
Shares Outstanding33.8%55.0041.0028.0028.0028.0028.0014.0013.0013.0013.008.006.00---------
Float----280---26.00---130---101---73.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations36.9%-19,094-30,238-14,258-10,696-13,253-10,664-10,249-10,061-12,559-6,286-7,749-7,400-8,716-8,061-9,969-7,466-6,989-7,770-6,474-5,738-6,587
  Share Based Compensation33.1%2,7542,0691,6941,3311,2201,0731,1551,1171,2099721,0101,014366305375--285378441408
Cashflow From Investing-6161.5%-126,231-2,016-4.00-57,920194,992-135,1801,950-6,800-27,099-39,000--26,445-20,0102,00039,742-15,432-3,50413,6513,509-17,738
Cashflow From Financing61.2%141,80787,97811027337.00120,397---17.006.00-104,26131.008,9406,26525,6243,77297319220,683
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ATXS Income Statement

2024-03-31
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 15,726$ 8,033
General and administrative8,4245,460
Total operating expenses24,15013,493
Loss from operations(24,150)(13,493)
Other income (expense):  
Interest and investment income4,2412,321
Other expense, net(19)(16)
Total other income, net4,2222,305
Net loss$ (19,928)$ (11,188)
Net loss per share attributable to common shareholders - basic$ (0.38)$ (0.40)
Net loss per share attributable to common shareholders - diluted$ (0.38)$ (0.40)
Weighted-average common shares outstanding used in net loss per share - basic52,294,76527,944,458
Weighted-average common shares outstanding used in net loss per share - diluted52,294,76527,944,458

ATXS Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 172,012$ 175,530
Short-term investments197,89571,000
Prepaid expenses and other current assets4,6144,412
Total current assets374,521250,942
Right-of-use asset210363
Other assets4,0763,361
Total assets378,807254,666
Current liabilities:  
Accounts payable8621,513
Accrued expenses10,0429,708
Current portion of operating lease liabilities168329
Total current liabilities11,07211,550
Total liabilities11,07211,550
Commitments (Note 6)
Stockholders' equity:  
Common stock, $0.001 par value per share, 150,000,000 shares authorized; 54,903,061 and 41,034,797 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively5541
Additional paid-in capital872,832728,285
Accumulated other comprehensive loss(14) 
Accumulated deficit(600,462)(580,534)
Total stockholders' equity367,735243,116
Total liabilities and stockholders' equity378,807254,666
Preferred stock  
Stockholders' equity:  
Preferred stock
Series X redeemable convertible preferred stock  
Stockholders' equity:  
Preferred stock$ 95,324$ 95,324
ATXS
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
 CEO
 WEBSITEastriatx.com
 INDUSTRYBiotechnology
 EMPLOYEES45

Astria Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for Astria Therapeutics, Inc.? What does ATXS stand for in stocks?

ATXS is the stock ticker symbol of Astria Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Astria Therapeutics, Inc. (ATXS)?

As of Tue Jun 18 2024, market cap of Astria Therapeutics, Inc. is 493.67 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATXS stock?

You can check ATXS's fair value in chart for subscribers.

What is the fair value of ATXS stock?

You can check ATXS's fair value in chart for subscribers. The fair value of Astria Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Astria Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATXS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Astria Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether ATXS is over valued or under valued. Whether Astria Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Astria Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATXS.